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Goto et al.

Superior Long-Term Outcomes of Adult
Living Donor Liver Transplantation:
A Cumulative Single-Center Cohort
Study With 20 Years of Follow-Up

Toru Goto,1,2,* Tommy Ivanics ,1,3,4,* Mark S. Cattral,1 Trevor Reichman,1 Anand Ghanekar,1
Gonzalo Sapisochin,1 Ian D. McGilvray,1 Blayne Sayed ,1 Les Lilly,1 Mamatha Bhat,1
Markus Selzner,1 and Nazia Selzner 1
1 Multiorgan Transplant Program, Toronto General Hospital, University of Toronto, Toronto, ON, Canada; 2 Department of
Surgery, Division of Hepato-Biliary-Pancreatic Surgery & Transplantation, Kyoto University Graduate School of Medicine, Kyoto,
Japan; 3 Department of Surgery, Henry Ford Hospital, Detroit, MI; and 4 Department of Surgical Sciences, Uppsala University,
Akademiska Sjukhuset, Uppsala, Sweden

Living donor liver transplantation (LDLT) is an attractive alternative to deceased donor liver transplantation (DDLT).
Although both modalities have similar short-term outcomes, long-term outcomes are not well studied. We compared the 20-
year outcomes of 668 adults who received LDLT with1596 DDLTs at the largest liver transplantation (LT) program in Canada.
Recipients of LDLT were significantly younger and more often male than DDLT recipients (P < 0.001). Autoimmune diseases
were more frequent in LDLT, whereas viral hepatitis and alcohol-related liver disease were more frequent in DDLT. LDLT
recipients had lower Model for End-Stage Liver Disease scores (P = 0.008), spent less time on the waiting list (P < 0.001), and
were less often inpatients at the time of LT (P < 0.001). In a nonadjusted analysis, 1-year, 10-year, and 20-year patient survival
rates were significantly higher in LDLT (93%, 74%, and 56%, respectively) versus DDLT (91%, 67%, and 46%, respectively;
log-rank P = 0.02) as were graft survival rates LDLT (91%, 67%, and 50%, respectively) versus (90%, 65%, and 44.3%, respectively, for DDLT; log-rank P = 0.31). After multivariable adjustment, LDLT and DDLT were associated with a similar hazard
of patient and graft survival. Our data of 20 years of follow-up of LDLT from a single, large Western center demonstrates
excellent long-term outcomes for recipients of LDLT.
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Liver transplantation (LT) is the only curative treatment for patients with end-stage liver disease.
However, the limited availability of deceased donors
denies access to this lifesaving treatment to many
Abbreviations: A2ALL, Adult-to-Adult Living Donor Liver
Transplantation Cohort Study; AIH, autoimmune hepatitis; BMI,
body mass index; CI, confidence interval; CIT, cold ischemia time;
DDLT, deceased donor liver transplantation; EBL, estimated blood
loss; FFP, fresh frozen plasma; GRWR, graft-to-recipient weight
ratio; HAT, hepatic artery thrombosis; HBV, hepatitis B virus; HCC,
hepatocellular carcinoma; HCV, hepatitis C virus; HR, hazard ratio;
ICU, intensive care unit; INR, international normalized ratio; IQR,
interquartile range; LDLT, living donor liver transplantation; LT,
liver transplantation; MELD, Model for End-Stage Liver Disease;
NASH, nonalcoholic steatohepatitis; OPTN, Organ Procurement

recipients: approximately 25% to 30% of patients die
each year while waiting for a liver graft. To reduce waitlist mortality, many programs initiated living donor LT
(LDLT) 2 decades ago as an alternative to deceased
donor LT (DDLT). LDLT provides many advantages over DDLT, including timely access that enables
transplantation when the recipient is in a better state of
health, planned elective surgery, higher quality grafts
from younger donors, and shorter cold ischemia times
(CITs).(1) A recent meta-analysis of controlled trials
revealed that LDLT showed a comparable perioperative mortality rate with DDLT despite a higher rate of
surgical complications.(2)
The Toronto adult LDLT program began in April
2000(3-10) to decrease waitlist mortality for adults with
end-stage liver disease. We reported previously that in
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a matched cohort study, hospital stay and short-term
survival were comparable for LDLT and DDLT recipients.(11) Herein, we report the cumulative 20-year
experience of LDLT at the Toronto General Hospital,
University Health Network. The main purposes of this
study were to compare the long-term patient and graft
survival rates between LDLT and DDLT and analyze
detailed longitudinal data on causes of death and graft
loss. This study represents the longest follow-up of
LDLT recipients from a single Western center.

Liver Transplantation, Month 2022

Primary LTs at Toronto General Hospital
January 2000-December 2019 (n = 2353)

Left liver graft (n = 8)
Fulminant liver failure (n = 80)
Age <18 years at transplant (n = 1)

Patients and Methods

(Patients may meet multiple exclusion criteria)

STUDY DESIGN

This study was a retrospective cohort study, which was
reviewed and approved by the Research Ethics Board at
Toronto General Hospital/University Health Network
(no. 18-6045). All clinical investigations were conducted
in accordance with the Declaration of Helsinki principles (2000) for medical research in human participants.
All cumulative data of donors and recipients who underwent primary LT from April 2000 to April 2020 at
Toronto General Hospital were collected using electronic
patient records and analyzed. LT from donors after cardiocirculatory death, pediatric recipients (younger than
age 18 years) at transplantation, patients with fulminant
hepatic failure, and patients who received combined solid
organ transplantations were excluded (Fig. 1).
and Transplantation Network; OR, operating time; PRBC, packed
red blood cells; PSC, primary sclerosing cholangitis; PVT, portal vein
thrombosis; WIT, warm ischemia time.
Address reprint requests to Nazia Selzner, M.D., Ph.D., Multiorgan
Transplant Program, Toronto General Hospital, University of Toronto,
700 University Avenue, Toronto, ON, Canada. Telephone: 416-340-
5166; FAX: 416-340-3378; E-mail: Nazia.Selzner@uhn.ca
*These authors are co-f irst authors.
The database that supports the findings of this study is available from
the corresponding author. Restrictions apply to the availability of the
data.
Additional supporting information may be found in the online version
of this article.
© 2021 by the American Association for the Study of Liver Diseases.
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Included in the analysis (adult primary LTs)
2000-2019 (n = 2264)

DDLT

LDLT

(n = 1596)

(n = 668)

FIG. 1. Flowchart of patient inclusion and exclusion.

OUTCOMES

The primary endpoint was the long-term patient and
graft survival during 20 years of follow-up. The secondary endpoint was the incidence of causes of graft
loss or patient death in both groups.

TRANSPLANTATION PROTOCOL
AND FOLLOW-UP

The selection criteria and operative procedure of LDLT
and DDLT were described previously.(3,4,8,9,10,11)
At Toronto General Hospital, all patients were registered on the waiting list for DDLT and were also offered the option of LDLT, regardless of their original
diseases and their severity. To ensure donor safety,
we have incorporated standard operating procedures
and policies developed by a collaborative multidisciplinary team.(9,10) Living donation is voluntary and
altruistic, and donors and recipients are informed
of the complications and survival rates in our program before surgery. Right lobe grafts with or without the middle hepatic vein were transplanted; the
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graft-to-recipient weight ratio (GRWR) was ≥0.8 in
most LDLT recipients.
For immunosuppressive therapy, all patients
received steroid induction as per our program protocol.(5,11) In addition, all LDLT recipients received
an additional induction agent, either thymoglobulin
or basiliximab (Simulect; Novartis Pharmaceuticals
Company, East Hanover, NJ). Basiliximab or thymoglobulin was used selectively in DDLT patients
if renal dysfunction or neurologic impairment was
present at the time of transplant. Steroids were rapidly tapered to a low dose of prednisone in the first
few months and stopped within 3 to 6 months if
there was no evidence of rejection; only a minority of
patients continued on low-dose maintenance prednisone. Calcineurin inhibitors were also used for
maintenance therapy: cyclosporine (Neoral; Novartis
Pharmaceuticals Company) for patients with chronic
hepatitis C virus (HCV ) infection and tacrolimus
(Prograf; Astellas Pharma US, Inc., Deerfield, IL) for
all other patients. Mycophenolate mofetil (Cellcept;
Hoffman-La Roche, Inc, Nutley, NJ) was used selectively at the attending physician’s discretion at doses
up to 2000 mg/day.

diseases, hepatocellular carcinoma (HCC) recurrence,
de novo cancer, cardiovascular events, stroke, hepatic
artery thrombosis (HAT), portal vein thrombosis
(PVT), infections, and others. Cases where the cause
of death could not be determined were categorized as
“others.” The causes of graft loss were analyzed in 2
periods: the first 5 years and after 5 years.

STATISTICAL ANALYSIS

Descriptive data for continuous variables were expressed as median with interquartile range (IQR).
These were compared using the Mann-W hitney U
test. Categorical variables were expressed as numbers
and percentages and were compared using chi-square
and Fisher’s exact test. Graft loss was defined as patient death or retransplantation. Patient and graft
survival were analyzed from the time of LT using
Kaplan-Meier curve analysis with log-rank tests.
An additional Kaplan-Meier curve analysis was performed to compare the 2 groups from the time of
listing. A sensitivity analysis of survival from LT was
performed for patients with MELD scores greater
than 25 at LT. The proportional hazard assumption
was assessed using Schoenfeld residuals against the
transformed time. Graft type (DDLT and LDLT)
COVARIATES
was not a time-dependent covariate. Cox proporWe retrieved clinical characteristics from our elec- tional hazard regression models were constructed to
tronic database, including recipient age, recipient evaluate the association of graft type on post-LT pasex (male or female), recipient location at LT (home, tient and graft survival. The effect of the exposure of
intensive care unit [ICU], rehabilitation, ward, and interest (graft type) was assessed by multivariable adunknown), Model for End-S tage Liver Disease justment of clinically deemed confounding variables.
(MELD) score at transplant, original liver disease A total of 4 separate Cox proportional hazard models
etiology (autoimmune hepatitis [AIH], alcohol- were constructed to evaluate the association between
related cirrhosis, hepatitis B virus [HBV ], HCV, graft type on patient and graft survival, which evalhepatoma, metabolic disorder, nonalcoholic steato- uated events in the full follow-up time of the study
hepatitis [NASH], primary biliary cholangitis, pri- cohort. In the first model, hazard ratios (HRs) commary sclerosing cholangitis [PSC], and other), donor paring posttransplant mortality and graft loss hazage, donor sex (male or female), graft type, type of ards were estimated without adjustment for donor
biliary anastomosis (duct-to-duct, Roux-en-Y ), and recipient characteristics. In the second model,
CIT (minutes), warm ischemia time (WIT) (min- HRs were estimated with adjustment for recipient
utes), operation time (minutes), estimated blood factors only (recipient age at transplant, etiology of
loss (EBL; mL), and intraoperative transfusion type liver disease, HCC, location of recipient at the time
(units; packed red blood cells [PRBC], fresh frozen of transplant, MELD score). In the third model,
HRs were estimated with adjustment for donor facplasma [FFP], platelets).
tors and ischemia times only (CIT, WIT, and donor
age). In the fourth model, HRs were estimated with
CAUSES OF DEATH/GRAFT LOSS
adjustment for donor and recipient factors. Models
Causes of death or graft loss were categorized as fol- for patients without HCC were built separately as
lows: biliary complications, recurrence of primary a sensitivity analysis. All statistical analyses were
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performed using R (R version 4.0.3 [2020-10-10],
R Foundation for Statistical Computing, Vienna,
Austria; http://www.R-project.org/).

Results

PATIENT CHARACTERISTICS

A total of 2264 recipients met the inclusion criteria
for the study: 668 LDLTs and 1596 DDLTs. The
median follow-up duration was 4.7 years (IQR,
1.5-10.1 years). Patient and operation characteristics are displayed in Table 1. LDLT recipients were
significantly younger and more often male compared
with DDLT recipients. Significant differences were
observed in the etiology of the underlying liver diseases (P < 0.001), with LDLT recipients having
more autoimmune diseases, including PSC (5.8%
versus 15.6%), primary biliary cholangitis (3.1% versus 8.8%), AIH (3.1% versus 4.9%), whereas DDLT
showed more patients with viral hepatitis (HBV,
14.6% versus 5.1%; HCV, 32.7% versus 27.8%) and
alcohol-related cirrhosis (19.7% versus 14.7%). A
higher proportion of patients also received a transplant for HCC (either a known diagnosis or incidental
findings) in the DDLT group (46.6% versus 27.4%;
P < 0.001). LDLT recipients had significantly lower
medical MELD scores at transplant (median [IQR],
16 [11-25] versus 15 [12-20]; P = 0.008), with
shorter waiting time from listing to transplantation
(median [IQR], 183 [37-365] versus 110 [73-219];
P < 0.001) and were less often inpatients (17% versus
30%; P < 0.001). As expected, donor age was significantly lower in the LDLT group when compared
with DDLT (50 years versus 38 years; P < 0.001),
with slightly more female donors in the LDLT
group. Both CIT (median minutes [IQR], 450 [353-
549] versus 95 [61-129]; P < 0.001) and WIT (median minutes [IQR], 50 [42-59] versus 47 [39-60];
P = 0.015) were shorter in LDLT, but EBL volumes
were similar. Intraoperative transfusions of PRBC,
platelets, and FFP in LDLT were significantly lower
(Table 1). In the LDLT group, 54.5% had a bilio-
enteric anastomosis with a Roux-en-Y compared
with 12.7% in the DDLT group (P < 0.001). The
LDLT group had a significantly higher rate of HAT
(2.2%) versus DDLT (0.8%; P = 0.005) and a higher
proportion of retransplantations (6.1% versus 2.4%;
P < 0.001). No difference was seen in the rate of
PVT between both groups. These results indicate
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higher frequencies of LDLT in younger recipients
with lower MELD scores and autoimmune diseases.

PATIENT SURVIVAL

Patient survival at 1 year, 5 years, 10 years, 15 years, and
20 years (95% confidence interval [CI]) for LDLT versus
DDLT were as follows: 1-year LDLT, 93.3% (95% CI,
91.4%-95.2%) versus DDLT, 91.3% (95% CI, 89.9%-
92.7%; P = 0.13); 5-year LDLT, 83.8% (95% CI, 80.9%-
86.9%) versus DDLT, 79.0% (95% CI, 76.8%-81.3%;
P = 0.03); 10-year LDLT, 73.6% (95% CI, 69.5%-78.0%)
versus DDLT, 67.2% (95% CI, 64.2%-70.2%; P = 0.01);
15-year LDLT, 59.7% (95% CI, 53.1%-67.1%) versus
DDLT, 54.7% (95% CI, 50.7%-58.9%; P = 0.02); and
20-year LDLT, 56.3% (95% CI, 58.9%-64.9%) versus DDLT, 46.3% (95% CI, 40.8%-52.7%; P = 0.02).
Overall posttransplant survival is shown in Fig. 2. The
median survival was 17.8 years (95% CI, 16.2-Not applicable [NA]) in the DDLT group and was not reached
in the LDLT group (survival >50%). In the sensitivity
analysis, evaluating the survival from the time of listing
comparing the 2 groups favored LDLT, although this
was not statistically significant (Supporting Fig. 1).
In the unadjusted analysis from the time of transplant, LDLT was associated with an improved patient
survival overall relative to DDLT (HR, 0.80; 95% CI,
0.67-0.97; P = 0.02). Compared with DDLT, the
overall patient and graft survival was similar between
the graft types on risk-adjusted analysis, after adjustment for donor characteristics, and after adjustment
for recipient and donor characteristics (Table 2).

GRAFT SURVIVAL

Graft survival at 1 year, 5 years, 10 years,15 years, and
20 years (95% CI) for LDLT versus DDLT were as follows: 1-year LDLT, 90.6% (95% CI, 88.4%-92.8%) versus DDLT, 89.9% (95% CI, 88.4%-91.5%; P = 0.73);
5-year LDLT, 80.7% (95% CI, 77.6%-84.0%) versus
DDLT, 77.3% (95% CI, 75.1%-79.7%; P = 0.18);
10-year LDLT, 67.4% (95% CI, 63.0%-72.1%) versus DDLT, 65.1% (95% CI, 62.1%-68.2%; P = 0.27);
15-year LDLT, 53.0% (95% CI, 46.1%-60.9%) versus
DDLT, 52.7% (95% CI, 48.8%-57.0%; P = 0.32); and
20-year LDLT, 49.8% (95% CI, 42.2%-58.7%) versus DDLT, 44.3% (95% CI, 38.7%-50.7%; P = 0.32).
Overall posttransplant graft survival is shown in Fig. 3.
The median graft survival was 16.9 years (95% CI,
14.5-20.2) in the DDLT group and 15.7 years (95%
CI, 14.7-NA) in the LDLT group.

Liver Transplantation, Vol. 0, No. 0, 2022Goto et al.
TABLE 1. Recipient and Transplant Characteristics Stratified by Graft Type
DDLT (n = 1596)

LDLT (n = 668)

P Value

Recipient age at transplant, years

57 (50-62)

54 (47-61)

<0.001†

Male sex

1181 (74.0)

402 (60.2)

<0.001‡

BMI

28 (24-30)

27 (23-29)

<0.008

Total bilirubin at transplant, μmol/L

44 (21-128)

46 (25-97)

0.94

INR at transplant

1.5 (1.2-2.0)

1.4 (1.2-1.7)

<0.001

Recipient Characteristics

Creatinine at transplant, μmol/L

84 (67-118)

76 (64-104)

<0.001

MELD score at transplant*

16 (11-25)

15 (12-20)

0.008†

MELD score at transplant without HCC*

22 (16-29)

16 (20-22)

<0.001

MELD score at transplant greater than 25

370 (23.3)

65 (9.7)

<0.001
<0.001‡

Recipient location at transplant
Home

1120 (70.2)

554 (82.9)

ICU

87 (5.5)

5 (0.7)

Rehabilitation

1 (0.1)

0 (0.0)

387 (24.2)

109 (16.3)

Ward
Unknown
Time on waitlist, days

1 (0.1)

0 (0.0)

183 (37-365)

110 (73-219)

<0.001†

Etiology of original liver disease
AIH

50 (3.1)

33 (4.9)

Alcohol-related cirrhosis

314 (19.7)

98 (14.7)

HBV

233 (14.6)

34 (5.1)

HCV

522 (32.7)

186 (27.8)

Hepatoma (non-HCC)

21 (1.3)

12 (1.8)

Metabolic disorder

40 (2.5)

15 (2.2)

NASH

180 (11.3)

69 (10.3)

Others

94 (5.9)

58 (8.7)

Primary biliary cholangitis

50 (3.1)

59 (8.8)

PSC

92 (5.8)

104 (15.6)

HCC

743 (46.6)

183 (27.4)

<0.001‡

Donor age, years

50 (36-62)

38 (29-49)

<0.001†

Donor male sex

937 (58.7)

300 (44.9)

<0.001‡

Duct to duct

1377 (86.3)

303 (45.4)

Roux-en-Y

203 (12.7)

364 (54.5)

<0.001‡

Biliary anastomosis

Unknown

16 (1.0)

1 (0.1)

CIT, minutes

450 (353-549)

95 (61-129)

<0.001†

WIT, minutes

50 (42-59)

47 (39-60)

0.015†

449 (385-517)

540 (460-630)

<0.001†

2350 (1400-4000)

2000 (1325-4000)

0.352†

PRBC, units

4 (1-6)

2 (1-6)

<0.001†

Platelets, units

1 (0-4)

1 (0-3)

<0.001†

FFP, units

6 (2-10)

5 (2-8)

0.040†

Retransplantation

39 (2.4)

41 (6.1)

<0.001‡

HAT
PVT

13 (0.8)
3 (0.2)

15 (2.2)
2 (0.3)

0.005‡
0.607‡

OR time, minutes
EBL, mL

NOTE: Data are provided as median (IQR) or n (%).
*The MELD score represents medical MELD and not exception points.
†Kruskal-Wallis rank sum test.
‡Pearson chi-square test.
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FIG. 2. Posttransplant patient survival stratified by graft type.

TABLE 2. Impact of Graft Type (LDLT versus DDLT) on
Posttransplant Outcomes
Compared With DDLT
Overall HR (95% CI)

P Value

Patient survival

0.80 (0.67-0.97)

0.02

Graft survival

0.91 (0.77-1.09)

0.30

Patient survival

1.16 (0.86-1.57)

0.33

Graft survival

1.35 (1.03-1.77)

0.03

Posttransplant Survival
Unadjusted analysis

Adjusted for recipient characteristics*

Adjusted for donor characteristics†
Patient survival

0.94 (0.70-1.27)

0.68

Graft survival

1.12 (0.85-1.47)

0.43

1.00 (0.72-1.38)
1.17 (0.87-1.57)

0.99
0.29

Adjusted for recipient and donor
characteristics‡
Patient survival
Graft survival

*Adjusted for recipient age at transplant, etiology of liver disease,
location of recipient at the time of transplant, and MELD score at
transplant.
†Adjusted for CIT, WIT, type of biliary anastomosis (Roux-en-Y
or duct-to-duct), and donor age.
‡Adjusted for CIT, WIT, recipient age at transplant, etiology of
liver disease, location of recipient at the time of transplant, type
of biliary anastomosis, MELD score at transplant, and donor age.

Compared with DDLT, the overall hazard of
graft loss was similar between the graft types in the
unadjusted analysis and after adjustment for donor
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FIG. 3. Posttransplant graft survival stratified by graft type.

characteristics alone. After adjustment for recipient
characteristics alone, LDLT was associated with a
higher hazard of graft mortality (reference, DDLT;
HR, 1.35; 95% CI, 1.03-1.77; P = 0.03; Table 2) This
effect was attenuated after adjustments for both donor
and recipient characteristics, with no statistically significant difference noted in the hazard of graft loss
with LDLT (reference, DDLT).

CAUSES OF DEATH/GRAFT LOSS

The cause of graft loss was classified into 10 different
categories in Tables 3 and 4. For patients who experienced graft failure in the first 5 years after LT, the
LDLT group had a higher rate of biliary complications
(5% versus 2%; P = 0.04) and HAT (11% versus 3%;
P = 0.003), whereas the DDLT group has a significantly higher rate of graft loss from de novo cancer
(Table 3). For patients who experienced graft failure/
death 5 years or more after LT, cardiovascular events
were higher in the LDLT group (21% versus 8%;
P = 0.008; Table 4).

Discussion

This is the largest single-center experience with the
longest follow-up period of LDLT in adults reported
by a single Western country LT program. Currently,
LDLT constitutes approximately one-third of the

Liver Transplantation, Vol. 0, No. 0, 2022Goto et al.
TABLE 3. Cause of Graft Loss: First 5 Years After LT Stratified by Graft Type
Cause of Graft Loss

DDLT (n = 303)

LDLT (n = 114)

P Value*

Biliary complications

5 (2)

6 (5)

0.040

Recurrence of primary disease

32 (11)

9 (8)

0.415

HCC recurrence

36 (12)

8 (7)

0.150

De novo cancer

63 (21)

14 (12)

0.046

Cardiovascular events

23 (8)

5 (4)

0.244

7 (2)

5 (4)

0.261

Infections

Stroke

45 (15)

25 (22)

0.085

HAT

10 (3)

12 (11)

0.003

PVT
Others

1 (0)
80 (26)

2 (2)
25 (22)

0.125
0.348

NOTE: Data are provided as n (%).
*Pearson chi-square test.
TABLE 4. Cause of Graft Loss: 5 Years or More After LT Stratified by Graft Type
Cause of Graft Loss

DDLT (n = 155)

LDLT (n = 66)

P Value*

Biliary complications

2 (1)

3 (5)

0.136

Recurrence of primary disease

15 (10)

11 (17)

0.140

HCC recurrence

11 (7)

3 (5)

0.476

De novo cancer

35 (23)

11 (17)

0.322

Cardiovascular events

13 (8)

14 (21)

0.008

Stroke
Infections
HAT
PVT
Others

3 (2)

1 (2)

0.830

24 (16)

8 (12)

0.516

3 (2)

2 (3)

0.616

2 (1)
46 (30)

0 (0)
14 (21)

0.352
0.195

NOTE: Data are provided as n (%).
*Pearson chi-square test.

adult LTs performed each year at our center. We report LDLT outcomes with a 20-year patient survival
rate exceeding 60%. The post-LT mortality hazard of
LDLT recipients was similar to DDLT after risk adjustment for DDLT. This report demonstrates the success of the LDLT procedure with excellent long-term
outcomes of a well-characterized cohort in a single
center and endorses the benefit of LDLT to decrease
mortality on the waiting list for adult recipients with
low MELD scores and long waiting times.
Although similar short-term patient survival
results were reported by several retrospective and
prospective studies with large registry data, to our
knowledge, our study is the only study reporting
on 20 years of follow-up data from LDLT recipients from a large, single-center Western country.
Hoehn et al.(12) retrospectively evaluated the data of

715 LDLT patients at 35 centers and 14,282 DDLT
patients at 62 centers from 2007 to 2012 collected
by the Scientific Registry of Transplant Recipients
and the Organ Procurement and Transplantation
Network (OPTN). Unadjusted analysis demonstrated that LDLT showed superior survival rates of
LDLT (P = 0.04) at 2 years after LT, but propensity score matching for 708 LDLT recipients showed
no difference in recipient (P = 0.41) and graft
(P = 0.72) survival rates. Gordon et al.(6) presented a
retrospective cohort study that included 2103 LDLT
and 46,674 DDLT patients of the national OPTN/
United Network for Organ Sharing data from 2002
to 2012.(6) Unadjusted survival analysis showed that
LDLT had significantly higher survival rates compared with DDLT patients (excluding the first 15
LDLT cases performed in each transplant center:
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5-year survival rate, 77.8% in LDLT versus 71.0%
in DDLT; P < 0.001). The Adult-to-Adult Living
Donor Liver Transplantation Cohort Study (A2ALL)
study,(13) which was a multicenter prospective study
in North America, demonstrated that LDLT recipients had significantly better survival probability
compared with DDLT (70% versus 64% at 10 years;
P = 0.02) in unadjusted analysis and was comparable in adjusted analysis by lower MELD score and
nonsevere renal dysfunction. These large database
series with short-term outcomes and our study with
long-term follow-up indicate that the better survival
rate in LDLT is based on favorable patient backgrounds, such as lower MELD scores, higher rates
of autoimmune diseases, fewer transplant patients
from ICU and inpatient wards, and lower rates of de
novo malignant etiology. The lower rates of de novo
malignancy in LDLT recipients may be attributed to
the presence of fewer risk factors based on the underlying etiologies, such as more autoimmune diseases
in this group.
However, the cause of death during the entire study
period showed no significant differences between the
2 groups in our study, similar to the A2ALL study.
We analyzed causes of graft loss at 2 different time
points: early term (from 0 to 5 years after transplantation) and late term (from 5 to 20 years). Within the
group of patients experiencing a graft loss within the
first 5 years, LDLT recipients had more biliary complications and more often HAT. Consequently, the rate
of retransplantation was higher in the LDLT group,
presumably attributed to a higher rate of early HAT.
Of note, despite a significantly higher rate of graft loss
attributed to HAT in the LDLT group, the overall rate
of HAT in our study is low (2% in LDLT versus <1%
in DDLT), indicating center expertise. Similarly, the
overall impact of graft loss attributed to biliary complications in our cohort of LDLT is low (5%) compared
with previously reported higher incidence of biliary(2,11,14,15,16,17,18,19,20) complications. Furthermore, no
differences in graft loss attributed to biliary or vascular
complications were observed between 5 to 20 years of
follow-up between both groups. Surprisingly, a higher
proportion of LDLT recipients in our study had graft
loss from cardiovascular complications such as myocardial infarction in the long term. Finally, our data
showed no difference in infection, recurrence of original diseases, and graft rejection as causes of graft loss.
In this study, we performed an unadjusted and
detailed survey of 2 different donor types in our
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cumulative history and evaluated the risk factor for
long-term outcomes in LDLT recipients. As this study
is neither prospective nor a matched cohort study, we
recognize that it may be limited by the different characteristics of each group and potential donor and recipient selection biases.
In conclusion, LDLT is an effective therapeutic
option that provides significant long-term benefits
with similar posttransplant patient and graft survival
rates as with DDLT. Our results demonstrate LDLT’s
benefits of less waiting times for transplantation and
overall equal long-term survival rates when performing
LDLTs in patients with lower MELD scores.
Acknowledgments: The authors thank Audrey Kim, a
clinical research technician, for valuable assistance with
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